Wyeth wins another diet drug trial

26 March 2006

US drug major Wyeth has announced that the jury in the cases of Joyce Townley versus Wyeth and Pamela Williams vs Wyeth in the Philadelphia Court of Common Pleas, which concerned claims of damages caused by the firm's long-withdrawn diet drugs, found in favor of the company in both cases.

"We are pleased with the verdicts and believe they were supported by the evidence," says Sean Laane, an attorney from Arnold & Porter, who represented Wyeth.

The trial began on March 15 before the Honorable Norman Ackerman.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight